Loading clinical trials...
Loading clinical trials...
A Phase II Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of AZD7442 in Chinese Adults
Conditions
Interventions
600 mg AZD7442 IV
600mg placebo IV
Locations
14
China
Research Site
Baoding, China
Research Site
Beijing, China
Research Site
Changsha, China
Research Site
Chongqing, China
Research Site
Fuzhou, China
Research Site
Haikou, China
Start Date
December 3, 2021
Primary Completion Date
August 15, 2022
Completion Date
May 6, 2023
Last Updated
November 21, 2024
NCT04425733
NCT05375760
NCT04391309
NCT05437289
NCT04742725
NCT04395170
Lead Sponsor
AstraZeneca
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions